New Technologies and Product Launches Drive Strong Revenue Growth and Certifications - Research Report on Hologic, Edwards Lifesciences, Volcano, Opko Health, and Wright Medical Group Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, August 8, 2013 NEW YORK, August 8, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Hologic Inc. (NASDAQ: HOLX), Edwards Lifesciences Corp. (NYSE: EW), Volcano Corporation (NASDAQ: VOLC), Opko Health, Inc. (NYSE: OPK), and Wright Medical Group Inc. (NASDAQ: WMGI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Hologic Inc. Research Report On August 5, 2013, Hologic Inc. (Hologic) reported its Q3 FY 2013 financial results (period ended June 29, 2013). The Company reported total revenues of $626.1 million, reflecting a 33.2% YoY growth, driven primarily by inclusion of Gen-Probe revenues, increased service revenues and higher sales of MyoSure hysteroscopic tissue removal (MyoSure) systems and breast biopsy products. Net loss was $11.0 million or $0.04 per diluted share, for the quarter, compared with net income of $23.6 million or $0.09 per diluted share, in Q3 FY 2012. Non-GAAP net income was $103.2 million or $0.38 per diluted share, compared to $92.6 million or $0.35 per diluted share in Q3 FY 2012. "We are pleased our third quarter revenues were in-line with and our EPS exceeded guidance. Although we have lowered expectations for the remainder of the fiscal year, I am confident we have the necessary platforms and breadth of assets to drive organic growth and deliver strong profitability," said Jack Cumming, President and Chief Executive Officer of Hologic. The Company anticipates full-year FY 2013 non-GAAP EPS of $1.46 to $1.47. The Full Research Report on Hologic Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/d132_HOLX] -- Edwards Lifesciences Corp. Research Report On August 5 2013, Edwards Lifesciences Corp. (Edward Lifesciences) announced that it has received a conditional Investigational Device Exemption (IDE) approval from the US Food and Drug Administration (FDA) for the initiation of a clinical trial of its Edwards SAPIEN 3 transcatheter aortic heart valve and accessories. "This valve builds on the SAPIEN platform and provides new features designed to benefit patients and enhance ease of use, such as a lower profile, a fabric cuff intended to reduce paravalvular leak and new delivery systems," said Larry L. Wood, Corporate Vice President, Transcatheter Heart Valves at Edward Lifesciences. "We appreciate the FDA's efforts to allow initiation of this trial in a timely way, providing U.S. patients with access to our most advanced transcatheter system." The Company informed that the trial will enroll up to 500 patients to study the SAPIEN 3 valve in the treatment of high-risk and inoperable patients with severe symptomatic aortic stenosis. The Full Research Report on Edwards Lifesciences Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/48b8_EW] -- Volcano Corporation Research Report On August 5, 2013, Volcano Corp. (Volcano) reported its Q2 2013 financial results. The Company posted revenues of $101.3 million, up 6.3% YoY during the quarter. GAAP net loss was $2.4 billion or $0.04 per share in Q2 2013, compared with net income of $3.3 million or $0.06 per diluted share in Q2 2012. Scott Huennekens, President and Chief Executive Officer of Volcano commented, "We continue to achieve market share gains and are setting the stage for future growth with initiatives such as our iFR (Instant Wave-Free Ratio) FFR technology. The launch of iFR in Europe is going very well and we just initiated our market launch in Japan." The Company reaffirmed its full-year 2013 outlook and expects revenues in the range of $394.0 to $400.0 million. The Full Research Report on Volcano Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/14bf_VOLC] -- Opko Health, Inc. Research Report On July 24, 2013, Opko Health, Inc. (Opko) announced that its Barcelona based subsidiary, Pharmadiet, S.L.U. has received a regulatory approval for the commercialization of its oral and injectable formulations of Citicoline, from the health authority of Spain, Agencia Española de Medicamentos y Productos Sanitarios. The Company expects to receive final marketing authorization for its product within 60 to 90 days. "OPKO plans to commercialize its oral and injectable citicoline products in Europe, Latin America, and other markets as well," said Phillip Frost, M.D., Chairman and Chief Executive Officer of Opko. The Full Research Report on Opko Health, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/cd43_OPK] -- Wright Medical Group Inc. Research Report On August 5, 2013, Wright Medical Group Inc. (Wright Medical) reported its Q2 2013 financial results. The Company posted net sales from continuing operations of $60.6 million, a 16.6% YoY growth on constant currency basis, during the quarter. Net loss from continuing operations for the quarter totaled $15.5 million or $0.34 per diluted share, compared to net loss of $1.4 million or $0.04 per diluted share in Q2 2012. Robert Palmisano, President and Chief Executive Officer of Wright Medical, commented, "The global foot and ankle business grew an outstanding 30% driven by continued sales productivity gains in our U.S. foot and ankle business, positive progress and focus on international market development and continued strong uptake of recent new foot and ankle product launches." The Company anticipates full-year 2013 net sales from continuing operations of c.$235 million to $240 million. The Full Research Report on Wright Medical Group Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/1782_WMGI] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. SOURCE Analysts' Corner Contact: CONTACT PERSON: Joe Thomas - CONTACT PHONE: +1-310-496-8071 (North America)
New Technologies and Product Launches Drive Strong Revenue Growth and Certifications - Research Report on Hologic, Edwards
Press spacebar to pause and continue. Press esc to stop.